Boston appeal against J&J award denied
This article was originally published in Clinica
The US Supreme Court has declined to hear Boston Scientific's appeal over the $703m in damages it has to pay for infringing a Johnson & Johnson coronary stent patent. The news dealt another blow to Boston's stock value, which slipped a further 7% yesterday to close at $10.33 per share. On September 30, a US district court in Delaware awarded J&J $1.2bn in damages against Boston and Medtronic. Boston took the brunt of the damages, while Medtronic was ordered to pay the $521m. The ruling was a culmination of an eight-year court battle between the three companies over the Palmaz balloon expandable stent patent, which is owned by J&J.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.